Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs IRWD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRWD Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

IRWD Overall Winner 6-Pillar Tally: VNDA 0 – 6 IRWD Matrix Metrics: VNDA 3 – 7 IRWD

As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas IRWD carries 34.8/100 (SELL) at $4.84 (12.3x Forward P/E, 62.9% operating margin).

  • Composite vs. Pillar Nuance: While VNDA currently prints a higher short-term Unified Composite Score (49.0/100 HOLD vs. IRWD 34.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -77.6% operating margin) and revenue trajectory (+9.0% vs. +24.1% YoY).
  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 75.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs IRWD
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
IRWD NASDAQ Head-to-Head Winner
Ironwood Pharmaceuticals, Inc. - Class A
Pharmaceutical Preparations
$4.84
+0.31% 1D
Market Cap $802.9M
TTM Revenue $400M
Forward P/E 12.3x
Beta / 30D Vol 1.38β · 54% Vol
Unified Composite Score
34.8 / 100 SELL
Tech 50.0 Fund 33.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 76
RSI-14: 75.5 · SMA20: $4.00 · SMA50: $3.98

6-Pillar Scorecard Institutional Category Breakdown (VNDA 0 – 6 IRWD)

Columns: Metric · VNDA · IRWD
1. Valuation Multiples IRWD
Forward P/E 103.1x 12.3x
Trailing P/E 103.1x 5.4x
PEG Ratio 2.23x N/M
EV / Revenue 0.9x 2.6x
2. Growth & Scale IRWD
Revenue Growth (YoY) +24.1% +9.0%
Earnings Growth (YoY) -95.9% +57.0%
TTM Revenue (USD) $229M $400M
Market Cap $238.9M $802.9M
3. Profitability & Quality IRWD
Gross Margin 93.6% 76.4%
Operating Margin -77.6% 62.9%
Net Profit Margin -119.9% 37.4%
Return on Equity (ROE) -82.5% -574.7%
4. Balance Sheet & Cash Flow IRWD
Cash Generation (TTM) -$150M $205M
Cash Flow Margin -65.4% 51.3%
Net Cash / Leverage $40M Net Cash $250M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IRWD
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 163.3% (75th %ile) 63.1% (6th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat IRWD
OpEx & R&D Intensity N/A 13.5% of Rev ($54M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (3) vs IRWD (7)
Institutional Metric VNDA IRWD Criterion Row Edge
Market Capitalization
Scale
$238.9M $802.9M Larger Scale IRWD
Trailing P/E Ratio
Valuation
103.1x 5.4x Lower Multiple IRWD
Forward P/E Ratio
Valuation
103.1x 12.3x Lower Multiple IRWD
Revenue Growth (YoY)
Growth
+24.1% +9.0% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-77.6% 62.9% Higher Margin IRWD
Net Profit Margin
Profitability
-119.9% 37.4% Higher Margin IRWD
Return on Equity (ROE)
Capital Efficiency
-82.5% -574.7% Higher ROE VNDA
52-Week Range Position
Momentum
4% ($4–$10) 67% ($3–$6) Stronger Trend IRWD
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 1.38β · 54% Vol Lower Realized Risk IRWD
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 34.8 / 100 (SELL) Higher Composite VNDA
Trailing 12M Revenue (USD)
Operating Scale
$229M $400M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% 76.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev N/M PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) $205M ($250M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IRWD +44.26 pp
VNDA: -5.83% · IRWD: +38.43%
3M Horizon IRWD +42.65 pp
VNDA: -30.24% · IRWD: +12.41%
6M Horizon IRWD +76.01 pp
VNDA: -37.58% · IRWD: +38.43%
1Y Horizon IRWD +56.33 pp
VNDA: -12.56% · IRWD: +43.77%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VNDA Revenue IRWD Revenue VNDA Op. Margin IRWD Op. Margin Margin Leader
FY2018 $190M $350M 11.3% -43.5% VNDA
FY2019 $230M $430M 10.0% 28.0% IRWD
FY2020 $250M $390M 11.0% 36.7% IRWD
FY2021 $270M $410M 15.7% 56.1% IRWD
FY2022 $250M $410M 2.5% 61.0% IRWD
FY2023 $190M $440M -7.2% -213.5% VNDA
FY2024 $200M $350M -20.5% 26.5% IRWD
FY2025 $220M $300M -70.0% 33.3% IRWD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IRWD CONSOLIDATION
134d in phase · OBV ACCUMULATION
Current IV 63.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IRWD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IRWD Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $802.9M market capitalization and 62.9% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($54M)
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs IRWD Key Questions & Quantitative Answers

As of Nov 16, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas IRWD carries 34.8/100 (SELL) at $4.84 (12.3x Forward P/E, 62.9% operating margin). Composite vs. Pillar Nuance: While VNDA currently prints a higher short-term Unified Composite Score (49.0/100 HOLD vs. IRWD 34.8/100 SELL), IRWD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -77.6% operating margin) and revenue trajectory (+9.0% vs. +24.1% YoY). Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 75.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IRWD leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with IRWD at +9.0% YoY revenue growth and +57.0% YoY earnings growth on $400M TTM revenue (76.4% gross margin, 62.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VNDA cumulative revenue shifted +15.8% while IRWD shifted -14.3%. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($54M) (0 disclosures) for IRWD.

IRWD screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas IRWD trades at 12.3x Forward P/E, 5.4x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (51.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus IRWD (-574.7% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, IRWD carries 63.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.38β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.